Deborah Knobelman - Feb 1, 2023 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role
Chief Financial Officer
Signature
/s/ Mike Rhee, attorney-in-fact
Stock symbol
SNTI
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 04:20 PM
Previous filing
Oct 4, 2022
Next filing
Feb 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNTI Stock Option (Right to Buy) Award $0 +130K $0.00 130K Feb 1, 2023 Common Stock 130K $1.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date.